This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kiadis Pharma Completes Five-year Follow-up Of Its Phase I/II Clinical Study With Blood Cancer Product ATIR™ And Study Meets Primary Objective

In this Phase I/II study, 19 high-risk leukemia patients were treated with escalating doses of ATIR™ after a haploidentical HSCT. The five-year follow-up data show no transplant related mortality in the nine patients who received an efficacious dose of ATIR™. In addition, no Grade III-IV (life-threatening) acute Graft versus Host Disease (GvHD) was observed at any dose, which again compares favorably to standard of care matched unrelated donor transplantations, where (according to data from the CIBMTR) incidence of life-threatening GvHD is 30%. The strong five-year survival data also suggest that immune cells responsible for the Graft versus Leukemia effect are retained in ATIR™.  

The results of the study allowed selecting the optimal ATIR™ dose for further development. Data from this five-year study will be published in due course in a peer-reviewed medical journal.  

An international multi-center Phase II study including patients with AML, acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), to confirm and extend the data from the Phase I/II study, is now ongoing with topline results of the first phase expected in H1 2014.  

Manfred Ruediger ,  PhD ,  Chief Executive Officer of Kiadis Pharma ,  commented: "The results from this study, which spans five years, show that ATIR™ might change the way in which patients with hematological malignancies will be treated. These data show that ATIR™ not only prevents significant infections without eliciting life-threatening GvHD, but also strongly improves survival rates in patients with high-risk malignancies and very poor prognosis. Our currently ongoing international Phase II clinical study is designed to confirm and extend these data to expedite moving ATIR™ towards regulatory approval."

Dr. Denis-Claude Roy ,  Professor of Medicine at the  University  of  Montreal   and principal investigator for the study ,  added: "We are very excited about the long-term effects of ATIR™. In demonstrating very strong efficacy in minimizing post-transplantation risks and improving overall survival, these long-term data represent a potential major advancement in providing patients for whom a suitable matched donor is not available, with the opportunity to receive an HSCT from a mismatched family member with ATIR™ added as an adjunctive treatment."

About ATIR™

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs